VIA
CHRS icon

Vident Investment Advisory’s Coherus Oncology CHRS Stock Holding History

Vident Investment Advisory’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,197
Closed -$83.4K – 1213
2023
Q1 		$83.4K Buy
+12,197
New +$94.7K ﹤0.01% 1177

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vident Investment Advisory's CHRS Position: Q2 2023 in Review

Vident Investment Advisory sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 12,197 shares — an estimated $83.4K sold.

Vident Investment Advisory first reported a position in CHRS in Q1 2023 and held it in 1 quarter. The position peaked at $83.4K in Q1 2023. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

  • Vident Investment Advisory reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 12,197 Coherus Oncology shares in Q2 2023, an estimated $83.4K.
  • Vident Investment Advisory first reported a position in Coherus Oncology in Q1 2023 and held it in 1 quarter.
  • Vident Investment Advisory's Coherus Oncology position peaked at $83.4K in Q1 2023.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.